Balarama Gundapaneni, n/a

Director

Pfizer (Ownership Interest includes stock, stock options, patent or other intellectual property, Employment)

Poster(s):

• (P105) IMPROVED SURVIVAL WITH ~5 YEARS OF CONTINUOUS TAFAMIDIS TREATMENT AMONG PATIENTS WITH NYHA CLASS III TRANSTHYRETIN AMYLOID CARDIOMYOPATHY
  Thursday, October 27, 2022

  5:30 PM – 5:40 PM EDT